Schering and Organon reported that that they will continue research in male fertility control separately. Their research collaboration will therefore conclude at the end of the Phase II trial.

“For both Organon and Schering, as well as our clinical and scientific colleagues worldwide, this has been a long and demanding research program. However, we accept the challenge of developing what we have learned so far into a convenient contraceptive method for men. Male fertility control remains an important research area for Schering,” says Phil Smits, M.D., head of gynecology/andrology at Schering.

The trial medication and modes of administration were based on results from earlier studies showing that sperm production could be suppressed to contraceptive levels by the progestogen etonogestrel given as a subcutaneous implant, which was developed by Organon. At the same time, the resulting testosterone deficiency could be minimized with an injection of long-acting testosterone undecanoate, developed by Schering.

“The Phase II trial was important as it showed that a progestogen combined with testosterone can work as a male contraceptive,” comments David Nicholson, executive vp, global R&D, Organon. “Our next step is to find a way to make it easy to use and acceptable to the population.”

Both companies described the collaboration as constructive, but came to the conclusion that the administration route investigated in the trial, which combined an annual implant with three-monthly injections, would unlikely result in a product that would be acceptable for widespread everyday use. These firms remain committed to research in male contraception and will build on the knowledge gained from the collaboration to seek improvements in how such a contraceptive can be better administered.

Previous articleSurvival Impact of Biomarker Identified in Phase III Trial of Melanoma Drug
Next articleLuminex and Exiqon to Work Together on microRNA Products